MultiSafepay joins Ant International’s Antom to Enhance Digital Payments Services for SMEs in Europe
1.7.2024 16:12:00 EEST | Business Wire | Press release
MultiSafepay (MSP), an Amsterdam-based payment service provider, and Antom global merchant payment services (Antom), a leading payment and digitization services provider under Ant International, announced today that MultiSafepay has become a wholly-owned subsidiary of Ant International and will integrate with Antom to promote convenient, secure and accessible payment solutions and digitalization services to businesses, especially small and medium-sized enterprises (SMEs) across Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240701540843/en/
Olaf Geurs, CEO of MultiSafepay (left) and Gary Liu, General Manager of Antom Global (right), in a ceremony. (Photo: Business Wire)
MultiSafepay now serves merchants with omnichannel payment services connecting over 40 international payment methods, including cards, e-wallets, Buy-Now, Pay-Laters, internet banking, and more. Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. In addition to flexible, secure and reliable payment options, Antom brings a suite of marketing and digitalization services to empower local and regional businesses with more growth opportunities.
Through this strategic partnership, MultiSafepay will leverage Antom’s cutting edge technology and digital capabilities to further expand its product offerings and SME merchant coverage in the region.
Since 1999, MultiSafepay has been a pioneer simplifying payment for SME businesses. It provides world-class payment solutions to over 18,000 SMEs, empowering them to concentrate on their business while MSP optimizes payment success rates, payment handling and processing combined with a personal approach.
Olaf Geurs, CEO of MultiSafepay said, “The past 25 years have been an incredible journey. Together with our amazing team, we've bootstrapped MultiSafepay into a leading full-service PSP in Europe, overcoming countless obstacles along the way. The entrepreneurial spirit never sleeps, which is why we're partnering with Antom to unlock even greater growth potential for MultiSafepay's products and services, attracting even more businesses to our ecosystem.”
Gary Liu, General Manager of Antom Global said, “We are thrilled to join hands with MultiSafepay, a trusted industry innovator and our long-term partner. SMEs are the pillar of regional and global prosperity. With digital innovations, we look forward to building together more secure, flexible and efficient payment solutions with cross-sector partners, for small businesses to thrive in a truly inclusive and sustainable global commerce ecosystem.”
About MultiSafepay
MultiSafepay is a leading Netherlands-based payment services provider using cutting-edge in-house-developed technology to help businesses of all sizes focus on growth and innovation. It offers European companies a simple, tailored payments ecosystem for online, in-person, and omnichannel solutions through a single platform and integration. MultiSafepay offers a personal approach to payments, optimizing payment success rates and reducing complexities to allow businesses and platforms to concentrate and drive their growth.
About Antom
Ant International’s Antom is a leading provider of payment and digitization services to merchants worldwide. Antom provides one-stop, vertical-specific digital payment solutions to meet the payment needs for merchants of all sizes, especially SMEs. With a presence in over 150 markets, Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. Antom also provides digital marketing solutions and merchant digitization services to help merchant in digital operations and to better engage with their customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701540843/en/
Contacts
Media contact:
Ant International
Fanny Wu
chen.wc@antgroup.com
Ant International
Joshua Way
joshua.way@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom